Positron CEO and president RobertM. Guezuraga has left the company, the Houston-based developerof PET scanners announced this month. Gary B. Wood, the vendor'schairman, will assume Guezuraga's responsibilities on an interimbasis until a new CEO is found.
Positron CEO and president RobertM. Guezuraga has left the company, the Houston-based developerof PET scanners announced this month. Gary B. Wood, the vendor'schairman, will assume Guezuraga's responsibilities on an interimbasis until a new CEO is found.
Guezuraga had been a member of Positron's board of directorssince 1989 and its chief executive since 1990. He will continueto serve on Positron's board, the company said.
Positron has begun a search for a new chief executive and islooking for an individual with experience in marketing and acquisitions,according to the company.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.